F. Seta
New York Medical College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by F. Seta.
The FASEB Journal | 2007
Benjamin Biteman; Iram R. Hassan; Everald Walker; Alexander J. Leedom; Michael W. Dunn; F. Seta; Michal Laniado-Schwartzman; K. Gronert
In the immune‐privileged cornea, epithelial wounds heal rapidly with almost no scarring and, unlike in most other tissues, acute inflammation in the absence of infection is beneficial to healing. Molecular mechanisms, which account for this striking property, remain to be clearly defined, but they likely include autacoids that control leukocyte activation. Two prominent enzymes, 12/15‐lipoxygenase (LOX), which generates antiinflammatory lipid autacoids, and heme‐oxy‐genase (HO), which generates antioxidants and carbon monoxide, are highly expressed in human and mouse corneas. LXA4, an endogenous 12/15‐LOX product, proved to be a potent inhibitor of exacerbated inflammation and significantly increased re‐epithelialization in corneal wounds. In vivo deletion of 12/15‐LOX correlated with exacerbated inflammation and impaired wound healing in 12/15‐LOX−/− mice, a phe‐notype that was rescued by treatment with LXA4. More importantly, 12/15‐LOX−/− mice demonstrated impaired induction of HO‐1 in both acute and exacerbated inflammation. Topical LXA4 restored HO‐1 expression in 12/15‐LOX−/− mice and amplified HO‐1 gene expression in human corneal epithelial cells. HO‐2−/− mice, which fail to induce HO‐1, also demonstrated exacerbated inflammation in response to injury, a phenotype that, notably, correlated with a 50% reduction in endogenous LXA4 formation. Collectively, results demonstrate a critical role for LXA4 in inflammatory/reparative responses and provide the first evidence that 12/15‐LOX and HO systems function in concert to control inflammation.–Biteman, B., Hassan, I. R., Walker, E., Leedom, A. J., Dunn, M., Seta, F., Laniado‐Schwartzman, M., Gronert, K. Interdependence of lipoxin A4 and heme‐oxygenase in counter‐regulating inflammation during corneal wound healing. FASEB J. 21, 2257–2266 (2007)
American Journal of Pathology | 2006
F. Seta; Lars Bellner; Rita Rezzani; Raymond F. Regan; Michael W. Dunn; Nader G. Abraham; K. Gronert; Michal Laniado-Schwartzman
Journal of Biological Chemistry | 2002
Alexander Mezentsev; F. Seta; Michael W. Dunn; Naoya Ono; John R. Falck; Michal Laniado-Schwartzman
Prostaglandins & Other Lipid Mediators | 2007
F. Seta; Kiran Patil; Lars Bellner; Alexandre Mezentsev; Rowena Kemp; Michael W. Dunn; Michal Laniado Schwartzman
Journal of Pharmacology and Experimental Therapeutics | 2005
Alexandre Mezentsev; Vladimir Mastyugin; F. Seta; Silvia Ashkar; Rowena Kemp; D. Sudarshan Reddy; John R. Falck; Michael W. Dunn; Michal Laniado-Schwartzman
Investigative Ophthalmology & Visual Science | 2005
M. Laniado Schwartzman; Alexandre Mezentsev; F. Seta; Michael W. Dunn; N. G. Abraham; K. Gronert
Investigative Ophthalmology & Visual Science | 2006
F. Seta; Lars Bellner; Michael W. Dunn; N. G. Abraham; K. Gronert; Michal Laniado Schwartzman
Investigative Ophthalmology & Visual Science | 2006
Michal Laniado Schwartzman; F. Seta; Lars Bellner; Alexandre Mezentsev; Michael W. Dunn
Investigative Ophthalmology & Visual Science | 2006
Lars Bellner; F. Seta; N. G. Abraham; Michael W. Dunn; K. Gronert; M. Laniado Schwartzman
Investigative Ophthalmology & Visual Science | 2005
Alexandre Mezentsev; F. Seta; Rowena Kemp; Michael W. Dunn; M. Laniado Schwartzman